-
Views
-
Cite
Cite
M V Huisman, H.-C Diener, S J Dubner, J L Halperin, K J Rothman, C.-S Ma, S Lu, M Paquette, C Teutsch, L R Franca, K Zint, G Y H Lip, GLORIA-AF Investigators, P3862
A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics, European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy563.P3862, https://doi.org/10.1093/eurheartj/ehy563.P3862Close - Share Icon Share
Extract
Background/Introduction: Following the introduction of non-vitamin K antagonist oral anticoagulants (NOACs), treatment patterns for stroke prevention in patients with atrial fibrillation (AF) are changing. GLORIA-AF is a prospective, three-phase, global registry program, which assesses treatment patterns and outcomes in patients with AF. Phase III enrollment started ∼2 years after the first NOAC, dabigatran etexilate, was approved for stroke prevention in AF in the respective countries.
Methods: Newly diagnosed AF patients at risk of stroke were consecutively enrolled from January 2014–December 2016 at 935 clinical sites in 38 countries reflecting a wide variety of physicians and settings. Sites were eligible based on availability of both dabigatran and vitamin K antagonists [(VKA).
Results: 21,248 eligible patients (median age 71; 44.9% female) in four geographical regions were enrolled. Stroke risks were high (CHA2DS2-VASc score ≥2) for 85.6% of patients and 9.3% had known high bleeding risk (HAS-BLED ≥3). Overall, oral anticoagulation was prescribed in 82.2% of patients (NOACs: 59.5% and VKAs: 22.7%), antiplatelet drugs alone in 11.2%, and 6.6% of patients received no antithrombotic therapy. Use of oral anticoagulants (OACs) was lower in Asia (61.5% vs other regions, 87.4%) where patients were less often at high stroke risk (78.7% vs 87.3%) and more often at high bleeding risk (11.8% vs 8.7%) than in other regions.
